Dornase alfa for cystic fibrosis
BMJ 1995; 310 doi: https://doi.org/10.1136/bmj.310.6993.1533a (Published 10 June 1995) Cite this as: BMJ 1995;310:1533
Patients should not be denied a safe, effective treatment
- Andrew Bush,
- Duncan M Geddes,
- Margaret E Hodson,
- Mark Rosenthal,
- Robert Dinwiddie,
- Colin Wallis,
- David E Stableforth,
- Steven P Conway,
- James M Littlewood
- Consultant paediatrician Consultant physician Consultant physician Consultant paediatrician Royal Brompton Hospital, London SW3 6NP
- Consultant paediatrician Consultant paediatrician Hospital for Sick Children, Great Ormond Street, London
- Consultant physician Heartlands Hospital, Birmingham
- Consultant physician and paediatrician Seacroft Hospital, Leeds
- Consultant paediatrician St James's University Hospital, Leeds
EDITOR,—We were interested to read a paper in the Drug and Therapeutics Bulletin on dornase alfa,1 and as the clinicians in the United Kingdom with the most experience with dornase alfa we must profoundly disagree with the paper's conclusions that, on the evidence available, dornase alfa should not be added to the formulary. The trouble with any unsigned recommendation is that readers do not know how many clinicians with experience of cystic fibrosis, treatment with dornase alfa, or both, were responsible for the final draft. Similarly they cannot judge whether considerations of cost were paramount.
We have seen many patients improve considerably with this treatment, and in many cases there has been an improvement of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.